Vox, January 16, 2020. Designing medicine around the “average man” is so dangerous. We need more inclusivity in clinical trials — for women, for people over 65, and for people of color.
Read More »Tag: clinical trials
NCHR Comment on FDA’s Draft Guidance on Developing Drugs for Male Breast Cancer
October 28, 2019. Increased diversity and inclusion in clinical trials are important, and we agree with the FDA guidance that male patients with breast cancer should be included in clinical trials.
Read More »NCHR Comments on FDA’s Draft Guidance on Enhancing the Diversity of Clinical Trial Populations
August 6, 2019. There are reasons why a drug or device may be less safe or less effective for women, children, older patients, or certain ethnic or racial subgroups. These differences in results for under-represented subgroups may not be minor or trivial. This is why sufficient inclusion of under-represented groups is so important.
Read More »